The results of 20-year investigations of perfluorocarbon gas-transporting emulsions for biological and medical applications performed by russian biophysicists together with chemists and clinicists are reviewed. As a result of these investigations, the blood substitute perftoran was created. Now this commercial blood substitute has different applications in clinics of Russia and other countries.
Kinetic-dynamic aspects of the development of slow-release mesalazine, Pentasa (now an established treatment of inflammatory bowel disease (IBD)), and cyclosporin, a T cell selective immunosuppressant (still in the investigative phase), are reviewed as examples of Danish contributions at an early stage to international, clinical drug research. Apart from increasing the therapeutic options for patients with IBD, current and future studies with these (and other) drugs may add important clues to a more precise understanding of the basic pathogenetic mechanisms (e.g. cytokines, adhesion molecules) involved in these diseases. The future development and clinical implementation of novel drug designs in IBD and other gastrointestinal diseases may be expected to benefit from a continued or even closer collaboration between clinical gastroenterologists and basic research institutions, including the pharmaceutical industry at an early stage.
Over the past 40 years, Denmark has established a world reputation for the comprehensive nature and excellence of its headache research. Advances have been made in epidemiology, genetics, pathophysiology and treatment across the whole spectrum of headache entities. Moreover, the IHS classification of headache, the guidelines for clinical trials and text books on the basic mechanisms and management of headaches were initiated from Denmark. These achievements are a tribute to all those who have participated and to the continuing leadership of Jes Olesen.
At the Canadian Society of Pharmacology and Therapeutics Annual Meeting in Montreal on May 27, 2011 Richard Ian Ogilvie, Professor Emeritus of Medicine and Pharmacology at the University of Toronto was invited to present a lecture regarding his 45 year career in clinical pharmacology in Canada. In the lecture he identified the people and events that shaped his accomplished career.